Literature DB >> 26681903

Ivabradine (Corlanor) for Heart Failure: The First Selective and Specific I f Inhibitor.

Sally Tse, Nissa Mazzola.   

Abstract

Ivabradine (Corlanor) for heart failure: the first selective and specific I f inhibitor.

Entities:  

Year:  2015        PMID： 26681903      PMCID： PMC4671466     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  16 in total

Review 1.  Ivabradine: A Unique and Intriguing Medication for Treating Cardiovascular Disease.

Authors:  James J Nawarskas; Brandi N Bowman; Joe R Anderson
Journal:  Cardiol Rev       Date:  2015 Jul-Aug       Impact factor: 2.644

2.  The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY.

Authors:  Roberto Ferrari; Kim M Fox
Journal:  Eur Heart J       Date:  2015-04-28       Impact factor: 29.983

Review 3.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2012-12-12       Impact factor: 29.690

4.  Rehospitalization for heart failure: predict or prevent?

Authors:  Akshay S Desai; Lynne W Stevenson
Journal:  Circulation       Date:  2012-07-24       Impact factor: 29.690

5.  Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma.

Authors:  Taslima Bhuiyan; Mathew S Maurer
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-10

Review 6.  Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.

Authors:  Gordon F Rushworth; Philippe Lambrakis; Stephen J Leslie
Journal:  Ther Adv Drug Saf       Date:  2011-02

Review 7.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

Review 9.  Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.

Authors:  S Sulfi; A D Timmis
Journal:  Int J Clin Pract       Date:  2006-02       Impact factor: 2.503

Review 10.  Risk-benefit assessment of ivabradine in the treatment of chronic heart failure.

Authors:  Irmina Urbanek; Krzysztof Kaczmarek; Iwona Cygankiewicz; Pawel Ptaszynski
Journal:  Drug Healthc Patient Saf       Date:  2014-04-28
View more
  16 in total

1.  Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by β-blocker carvedilol.

Authors:  Ying Cao; Shujun Chen; Yemei Liang; Ting Wu; Jianxin Pang; Shuwen Liu; Pingzheng Zhou
Journal:  Br J Pharmacol       Date:  2018-09-09       Impact factor: 8.739

Review 2.  Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.

Authors:  Sonu Abraham; Anju Nohria; Tomas G Neilan; Aarti Asnani; Anu Mariam Saji; Jui Shah; Tara Lech; Jason Grossman; George M Abraham; Daniel P McQuillen; David T Martin; Paul E Sax; Sourbha S Dani; Sarju Ganatra
Journal:  J Am Coll Cardiol       Date:  2022-10-06       Impact factor: 27.203

3.  Simultaneous Optimization of Oral and Transdermal Nanovesicles for Bioavailability Enhancement of Ivabradine Hydrochloride.

Authors:  Marianne Joseph Naguib; Ibrahim Elsayed; Mahmoud Hassan Teaima
Journal:  Int J Nanomedicine       Date:  2021-04-21

4.  Pd(II)-Catalyzed Enantioselective C(sp3)-H Arylation of Cyclopropanes and Cyclobutanes Guided by Tertiary Alkylamines.

Authors:  Jesus Rodrigalvarez; Luke A Reeve; Javier Miró; Matthew J Gaunt
Journal:  J Am Chem Soc       Date:  2022-02-25       Impact factor: 16.383

Review 5.  If Channel as an Emerging Therapeutic Target for Cardiovascular Diseases: A Review of Current Evidence and Controversies.

Authors:  Hayelom G Mengesha; Tadesse B Tafesse; Mohammed H Bule
Journal:  Front Pharmacol       Date:  2017-11-24       Impact factor: 5.810

Review 6.  Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment.

Authors:  Victoria A Serhiyenko; Alexandr A Serhiyenko
Journal:  World J Diabetes       Date:  2018-01-15

7.  Ectopic Atrial Tachycardia in a 12-Month-Old Girl Treated With Ivabradine and Beta-Blocker, a Case Report.

Authors:  Holger Michel; Frank Heißenhuber; Sven Wellmann; Michael Melter; Stephan Gerling
Journal:  Front Pediatr       Date:  2020-06-16       Impact factor: 3.418

8.  Ivabradine for coronary artery disease and/or heart failure-a protocol for a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Authors:  M Maagaard; E E Nielsen; C Gluud; J C Jakobsen
Journal:  Syst Rev       Date:  2019-02-01

9.  Effects of adding ivabradine to usual care in patients with angina pectoris: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Authors:  Mathias Maagaard; Emil Eik Nielsen; Naqash Javaid Sethi; Liang Ning; Si-Hong Yang; Christian Gluud; Janus Christian Jakobsen
Journal:  Open Heart       Date:  2020-10

10.  Use of Preoperative Single Dose Ivabradine for Perioperative Hemodynamic Stabilization During Non-Cardiac Elective Surgery Under General Anaesthesia: A Pilot Study.

Authors:  Anwesha Banerjee; Sangamitra Mishra
Journal:  J Clin Med Res       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.